Navigation Links
Video: Jewelry Television(R) Introduces DermaGem(TM)
Date:5/4/2009

Gemstone-Based Skin Care Utilizes Breakthrough Technology of GemPlex 5(TM)

KNOXVILLE, Tenn., May 4 /PRNewswire/ -- Jewelry Television(R) announced the launch of DermaGem(TM), a new collection of skin care products and make-up sold exclusively on Jewelry Television(R) and JTV.com. DermaGem(TM) is the first line of luxury skin care products utilizing the breakthrough technology of GemPlex 5(TM), a proprietary ingredient blending the anti-aging benefits of gemstones with 21st century technology. The unique Gemplex 5(TM) formula -- a blend of four gem extracts and wild yam -- is designed to bathe the skin with protective hydration to combat the drying effects of our environment. Gem extracts of rhodolite, hematite, malachite and smithsonite each possess unique antioxidant qualities and other helpful components that may promote the collagen and elastin synthesis that supports healthy youthful skin.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/dermagem/33432/

(Photo: http://www.newscom.com/cgi-bin/prnh/20090504/NY10369 )

The collection was co-created by internationally known skin care consultant, J.J. Meier after five years of research and development in France and California. "My focus was to use nature's organic materials in a blend that may boost defenses against environmental damage and the effects of aging on skin," explained Ms. Meier.

"We are pleased that Ms. Meier elected to deliver her proprietary skin care blend exclusively to Jewelry Television(R) customers," said Randy Puryear, Vice President, Merchandising Research for Jewelry Television(R). "We serve millions of female consumers each year and now they will have access to top-of-the-
'/>"/>

SOURCE Jewelry Television
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Video: CVS/pharmacy Pays Tribute to Caregivers and Announces Winners of the For All the Ways You Care Contest
2. Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element
3. Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines
4. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
5. Video: CVS Caremark Charitable Trust Awards $4.2 Million in Grants Benefiting Children with Disabilities, Uninsured
6. Video: Genworth Financial Reveals Best Places in America for Long Term Care
7. Video: Turning Hope Into Reality - Vision Research at the VA
8. Video: Turning Hope Into Reality - Traumatic Brain Injury Research at the VA
9. Video: Turning Hope Into Reality - Genomics Research at the VA
10. Video: Waters Highlights Impact of ACQUITY UPLC with Peer-to-Peer Scientist Testimonials
11. Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... Bill Germanakos to Deliver NBGH Keynote Address, ... DGX ), the leading provider of diagnostic ... Business Group,on Health (NBGH), an association of more ... Best Employers for Healthy Lifestyles Gold Award to ...
... with seizures, SEATTLE, May 13 The Epilepsy ... in,Seattle, Spokane and Portland. The events will occur on ... Spokane at Riverfront Park. The following,day, Sunday, June 22, ... take place from 9:30 am-12:00 pm., "Everyone is ...
... 13 The Board of Directors of,MSA (NYSE: MSA ... per,share on common stock, payable June 10, 2008 to shareholders ... a dividend of 56-1/4 cents per share on,preferred stock, payable ... About MSA:, Established in 1914, MSA is a ...
... tobacco smoke respond particularly well to montelukast (Singulair) ... Research Center. Associate Professor of Pediatrics Nathan ... biomarkers that may help physicians predict even more ... These findings will help doctors know in advance ...
... Center,for Adoption announces a $10,000 grant from the Aetna ... during pregnancy., Kimberlee Walters-Sanders, an Aetna sales representative ... Head of Sales, will,present the award to Gladney staff ... Gladney,s campus, located at 6300 John Ryan Dr., Fort,Worth., ...
... Both Proposals -, LAKE FOREST, Ill., May 13 ... specialty pharmaceutical and medication,delivery company, today held its 2008 ... votes on two proposals and a brief,update on the ... to the success of our strategies of investing,for growth, ...
Cached Medicine News:Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 2Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 3Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 4Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 5Health News:Girls and children exposed to tobacco smoke benefit more from montelukast (singulair) 2Health News:Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation 2Health News:Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders 2
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , , PHILADELPHIA , Jan. 14 ... centralized services to the biopharmaceutical, medical device and related industries, ... written by ERT experts. Each paper discusses issues relevant to ... as an experienced and reliable partner in products and services ...
... , HORSHAM, Pa. , Jan. 14 ... the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) ... today in The New England Journal of Medicine. ... doses of STELARA than with etanercept over a 12-week period. ...
Cached Medicine Technology:ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 2ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 3ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 4ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
Bone Curette, 180 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Townsend is a endocervical stainless-steel curette with round tapered tip....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: